



Managing neonates with respiratory failure due to SARS-CoV-2

Authors' reply

We thank Daniele De Luca for his reflections on our Comment.¹ We agree that testing all admitted neonates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not necessary. We recommended screening all newly admitted infants at high risk of coronavirus disease 2019 (COVID-19) on the basis of their family history. Only high-risk patients should receive a nucleic acid test for SARS-CoV-2. However, all high-risk neonates should be isolated in a single room, preferably in a neonatal intensive care unit (NICU). Based on existing experience, some patients initially present with mild flu-like symptoms but rapidly develop respiratory distress and multiple organ failure. Admitting all neonates with COVID-19 to the NICU could ensure the availability of close monitoring and necessary interventions.² However, each clinical setting should consider its bed surge capacity in case of a COVID-19 outbreak and adopt a flexible and variable approach to admitting patients.

We recommend an individualised treatment strategy in the management of patients with COVID-19. The pathological findings from a patient who died from COVID-19 are consistent with the histological rationale for neonatal acute respiratory distress syndrome (ARDS),^{3,4} indicating the probability of secondary impairment of surfactant function and pulmonary hypertension in the case of severe neonatal COVID-19. Therefore, surfactant administration and inhaled nitric oxide are expected to be effective in infants with severe COVID-19. We agree with the recommendation that a physiology-based ventilation method should be used and that extracorporeal life support should only be provided as a rescue approach.

We think the prescription of remdesivir and other antivirals in neonates should still be done with caution owing to the small amount of evidence regarding safety and efficacy in this population. Relatively reduced immune responses in children might contribute to their milder clinical manifestation in comparison with adults, so iatrogenic suppression of immunity should be done with caution, particularly in neonates. Meanwhile, clinical evidence does not support corticosteroid treatment for COVID-19 lung injury.⁵

We agree that universal treatment approaches remain undefined, so continuous updates are warranted.

We declare no competing interests.

Jianhui Wang, *Yuan Shi
shiyuan@hospital.cqmu.edu.cn

Department of Neonatology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China

- 1 Wang J, Qi H, Bao L, Li F, Shi Y. A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units. *Lancet Child Adolesc Health* 2020; published online Feb 7. [https://doi.org/10.1016/S2352-4642\(20\)30040-7](https://doi.org/10.1016/S2352-4642(20)30040-7).
- 2 Barfield WD, Papile LA, Baley JE, et al. Levels of neonatal care. *Pediatrics* 2012; **130**: 587–97.
- 3 Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; published online Feb 18. [https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X).
- 4 De Luca D, van Kaam AH, Tingay DG, et al. The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity. *Lancet Respir Med* 2017; **5**: 657–66.
- 5 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020; **395**: 473–75.

Published Online
March 6, 2020
[https://doi.org/10.1016/S2352-4642\(20\)30072-9](https://doi.org/10.1016/S2352-4642(20)30072-9)